AICAR

What is AICAR?

AICAR (5-aminoimidazole-4-carboxamide ribonucleoside, also known as acadesine) is a cell-permeable nucleoside analog that activates AMP-activated protein kinase (AMPK), the master metabolic sensor that the body normally activates during exercise. In a landmark 2008 study published alongside the PPARδ agonist GW1516, AICAR increased running endurance by 44% in completely sedentary mice — without any training. This made it the first pharmacological "exercise mimetic" and triggered immediate doping concerns. WADA banned it in 2009, and the French anti-doping agency raised concerns about its use during the Tour de France. AICAR is not a peptide — it's a nucleoside analog — but it occupies a central position in exercise mimetic and metabolic optimization research, with connections to SLU-PP-332, MOTS-c, and other compounds in the endurance enhancement space.

What AICAR Is Investigated For

AICAR is the original 'exercise in a pill' — an AMPK activator investigated for exercise endurance, metabolic syndrome, fat oxidation, diabetic neuropathy, and cardioprotection during ischemia. The most famous preclinical result is the 2008 Cell paper showing a 44% increase in running distance in sedentary mice over 4 weeks alongside an oxidative gene program and fat mass reduction — a striking finding that triggered WADA prohibition in 2009. The human record is more conclusive than 'mixed' suggests, and it is negative. A 1997 meta-analysis of five trials in bypass surgery reported reductions in myocardial infarction and early cardiac death, but the definitive test that followed — RED-CABG, 3,080 patients across 300 sites — was stopped early for futility, finding an odds ratio of 1.01 for its primary composite endpoint. A separate oncology programme in chronic lymphocytic leukaemia and myelodysplastic syndrome was halted when the 210 mg/kg dose caused serious renal side effects. No human trials exist for exercise performance, obesity, or longevity indications — the iconic endurance effect has never been reproduced in humans, WADA prohibition makes such trials difficult to run, and a 2021 systematic review documented numerous AMPK-independent AICAR effects that complicate earlier interpretations. It is also technically a nucleoside analog, not a peptide. The honest framing is strong preclinical rationale in rodents, unproven in humans for performance use, and prohibited in competitive sport.

History & Discovery

AICAR was first synthesized as a research tool in the mid-twentieth century, decades before its modern reputation as an exercise mimetic. As acadesine, it was developed clinically in the 1990s and 2000s by Gensia Sicor and later licensed to other sponsors as a cardioprotective agent — given intravenously around the time of coronary artery bypass surgery to limit ischemia-reperfusion injury. A 1997 JAMA meta-analysis pooling five randomised trials in 4,043 patients reported reductions in myocardial infarction and early cardiac death, though the two largest individual trials had each missed their prespecified primary endpoints. The question was settled in 2012 by RED-CABG, a 3,080-patient trial across 300 sites in 7 countries run by Merck: it was stopped early for futility, returned an odds ratio of 1.01 for its primary composite, and ended the cardiac programme. Acadesine was then redeveloped in oncology by the Spanish company Advancell under the name Acadra, with EU orphan designation for B-cell chronic lymphocytic leukaemia; a 24-patient Phase 1/2 set a maximum tolerated dose of 210 mg/kg without establishing efficacy, and a subsequent trial in azacitidine-refractory myelodysplastic syndrome was halted by its investigators because that dose caused serious renal side effects in several patients. The drug has never been approved for any indication. The scientific moment that pulled AICAR into the wellness and performance conversation came in 2008, when Vihang Narkar and colleagues in Ronald Evans's lab at the Salk Institute published a Cell paper showing that 4 weeks of AICAR injections increased running endurance by roughly 44% in completely untrained mice — alongside the PPARδ agonist GW1516, which produced similar effects only in exercised animals. The press immediately called it 'exercise in a pill.' WADA reacted in 2009 by adding AICAR to the Prohibited List under category S4 (Hormone and Metabolic Modulators), and developed mass-spectrometry assays to detect it in athlete urine. Reports surfaced of suspected use in professional cycling around the 2009 Tour de France, although confirmed positive cases came later. AICAR is technically not a peptide — it is a nucleoside analog of adenosine monophosphate — but it is so often discussed alongside peptide-based exercise mimetics like MOTS-c and SLU-PP-332 that it has become a standard reference compound in the space.

How It Works

When you exercise, your cells burn ATP for energy, and AMP levels rise. AMPK detects this rising AMP and activates programs that burn fat, make new mitochondria, and improve endurance. AICAR bypasses the need for actual exercise — it gets converted into ZMP inside cells, which directly activates AMPK as if you'd just worked out. Your muscles respond by switching on a set of genes that favour endurance metabolism and by burning more fat. Worth knowing: the muscle fiber-type change often attributed to AICAR actually belongs to a different drug in the same famous experiment.

AICAR is a cell-permeable nucleoside that enters cells via adenosine transporters and is phosphorylated by adenosine kinase to ZMP (5-aminoimidazole-4-carboxamide ribotide), an AMP analog that allosterically activates AMPK. Activated AMPK phosphorylates multiple downstream targets: ACC (increasing fatty acid oxidation), PGC-1α (stimulating mitochondrial biogenesis), GLUT4 (enhancing glucose uptake), and TSC2 (inhibiting mTOR-dependent anabolic pathways). In the landmark mouse study, two separate dosing arms are often collapsed into one: 250 mg/kg/day for 6 days was used for gene-expression analysis, where AICAR up-regulated a set of 32 genes linked to oxidative metabolism, while 500 mg/kg/day for 4 weeks was used for the treadmill tests, where treated sedentary mice ran roughly 44% further (and about 23% longer) than vehicle controls, with decreased epididymal fat mass and increased oxygen consumption. AICAR was not shown to shift muscle fiber type in that paper — the type I fiber increase of roughly 38%, and the mitochondrial DNA increase, belong to the PPARδ agonist GW1516 combined with exercise training, and GW1516 alone in sedentary animals changed neither. The transcriptional program required PPARδ: AICAR failed to induce oxidative gene expression in PPARδ-null cells. However, a systematic review identified numerous AMPK-independent AICAR effects, complicating interpretation of earlier studies that attributed all effects to AMPK activation.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about AICAR:

• 01Human exercise-performance data — the iconic 44% result is from sedentary mice, and no controlled human trial has tested whether trained or untrained humans gain endurance from AICAR dosing. The two human infusion studies that exist measured muscle glucose uptake rather than performance, and both found AICAR substantially weaker than expected: one recorded no change in AMPK activity or phosphorylation at all, the other no increase in muscle glucose uptake despite high plasma concentrations.
• 02Renal dose-response in humans. Perioperative infusion at 0.1 mg/kg/min was tolerated across thousands of cardiac surgery patients, while 210 mg/kg in oncology produced trial-stopping renal toxicity. Nothing characterises the territory between those two extremes, which is precisely where any self-administered dose would sit.
• 03Long-term safety of chronic AMPK activation — repeated activation of a master metabolic sensor has theoretical implications for cell division, neurodegeneration risk, and immune function that have not been studied beyond short windows.
• 04AMPK-independent effects — a 2021 systematic review documented numerous AICAR effects that are not mediated by AMPK; the practical safety significance of these off-target actions is not well characterized. 2026 mechanistic papers continue to broaden the tissue-effect landscape: AICAR improved depression-like behaviors with hippocampal neurogenesis and neuroinflammation modulation in a microbiota-disruption model (Neurochem Int, PMID 41932583), mitigated hypoxic corneal damage via energy homeostasis rebuilding (Chem Biol Interact, PMID 42392248), and alleviated thapsigargin-induced autophagic flux impairment and inflammation in human ARPE-19 retinal cells with CLN3 deficiency (Biochem Biophys Res Commun, PMID 42308764) — reinforcing that AICAR is a mechanistically messy research tool with effects extending well beyond skeletal-muscle AMPK activation.
• 05Oral bioavailability and route equivalence — AICAR is poorly orally bioavailable, but consumer markets often sell oral preparations whose pharmacokinetic equivalence to injection has not been demonstrated.
• 06Tissue-specific dose-response — published animal protocols use very high IP doses (250–500 mg/kg/day) that are not directly scalable to humans, and no human dose-ranging data exists.
• 07Interaction with training stimulus — whether AICAR enhances, blunts, or simply parallels the adaptive response to actual exercise in humans is unknown.

Forms & Administration

AICAR has been administered via intraperitoneal injection in animal studies (250-500 mg/kg/day) and intravenous infusion in human cardioprotection trials. It has poor oral bioavailability. It is not available through legitimate medical channels for performance or metabolic use. Banned by WADA.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

These numbers come from preclinical and surgical-trial literature, not consumer dosing guidelines. AICAR is not FDA-approved for any performance, metabolic, or longevity indication and is prohibited in competition.

Timeline of Effects

Monitoring & Measurement

Common Questions

Who AICAR Is NOT For

Drug & Supplement Interactions

Documented human drug-interaction data for AICAR is essentially limited to the acadesine perioperative literature; what follows is theoretical and derived from mechanism. The most consistent practical concern is hypoglycemia in the setting of insulin, sulfonylureas, or other antidiabetic agents — AICAR enhances skeletal-muscle glucose uptake and improves insulin sensitivity, and additive lowering of blood glucose is plausible. Metformin, which independently activates AMPK, may produce additive metabolic effects of unclear clinical magnitude. AICAR is metabolized in part through adenosine pathways. Theoretically, drugs that interact with adenosine signaling (dipyridamole, methylxanthines such as caffeine and theophylline, regadenoson) could modify AICAR's pharmacology, although the magnitude in humans is uncharacterized. Because AICAR acts as a ZMP precursor and AMP analog, it may interact with the regulation of nucleotide-dependent pathways, but no clinically actionable interaction list exists. Athletes and patients on any chronic medication should not assume the absence of documented interaction means absence of interaction.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions